 # Bioequivalence — Module 2 Project

Bioequivalence Study and Pharmacokinetic Analysis Using Python


📌 Project Overview

This project performs a rigorous statistical evaluation of bioequivalence between a generic drug formulation and a reference innovator product, strictly following regulatory guidelines from health authorities (such as EMA and FDA).The analysis evaluates whether the 90% Confidence Interval for the Geometric Mean Ratio (GMR) of the Area Under the Curve ($\text{AUC}$) falls entirely within the standard regulatory acceptance range of 80.00% to 125.00%.

🛠️ Technologies & Libraries (Python)

NumPy: Efficient array manipulation and logarithmic/exponential transformations.SciPy (scipy.stats): Statistical analysis, including Standard Error of the Mean (SEM) and Student's t-distribution quantiles (ppf).Jupyter Notebook / VS Code: Interactive data processing, code execution, and LaTeX Markdown reporting.


🔬 Mathematical & Statistical Methodology1. Trapezoidal Rule $text{AUC}$ 

Integration

$$\text{AUC}_{0-t} = \sum_{i=1}^{n} \frac{C_{i-1} + C_i}{2} \times (t_i - t_{i-1})$$


Log-Transformation ($\ln$)

Pharmacokinetic parameters ($\text{AUC}$) are assumed to follow a log-normal distribution

 Logarithmic transformation converts multiplicative ratios into additive differences:
 
 $$\Delta \ln(\text{AUC}) = \ln(\text{AUC}_{\text{generic}}) - \ln(\text{AUC}_{\text{reference}})$$


 90% Confidence Interval Estimation
 
 The confidence boundaries on the logarithmic scale are calculated using Student's t-critical value obtained via scipy.stats.t.ppf(0.95, df=n-1):


$$\text{SEM} = \frac{s}{\sqrt{n}}$$

$$\text{Margin of Error} = t_{\text{crit}} \times \text{SEM}$$


 Regulatory Decision CriteriaThe log confidence limits are exponentiated (exp) to back-transform them to the percentage ratio scale: 

$$80.00\% \le \text{Lower CI} \quad \text{and} \quad \text{Upper CI} \le 125.00\%$$
 

 📊 Summary of ResultsSample Size ($n$): 
 

 12 crossover subjectsPoint Estimate (GMR): 98.30%90% Confidence Interval: [98.10%, 98.51%]
 Regulatory Decision: BIOEQUIVALENT (The 90% CI lies entirely within the range [80.00 %, 125.00 %]).
 
 💡 Conclusion & SignificanceBioequivalence testing plays a crucial role in modern healthcare. Demonstrating bioequivalence ensures that generic medications deliver the exact same safety, quality, and therapeutic efficacy as the original innovator drugs. This enables patients to have continuous access to affordable, high-quality treatments, especially in situations where the original medication is unavailable, out of stock, or cost-prohibitive.Furthermore, evaluating bioequivalence requires deep mathematical and statistical expertise. Applying log-normal transformations, Student's t-distributions, and two one-sided testing (TOST) concepts guarantees that pharmaceutical comparisons are grounded in scientific rigor rather than random chance, ultimately protecting patient health and safety.


****Primary Academic Literature and Textbooks****



***Applied Biopharmaceutics Pharmacokinetics (7th Ed.) By Leon Shargel and Andrew B.C. Yu***


***Regulatory Guidelines & Official Standards***

European Medicines Agency (EMA): Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ).

U.S. Food and Drug Administration (FDA): Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations.

***Python Documentation & Scientific Libraries***

NumPy Developers: NumPy Reference Guide & Mathematical Functions. Available at: https://numpy.org/doc/

SciPy Community: SciPy Statistical Functions (scipy.stats). Available at: https://docs.scipy.org/doc/scipy/reference/stats.html

***Educational Online Resources & Lectures***

Interactive Jupyter Notebook Documentation: Markdown and LaTeX formatting guides for scientific computing.
 
